New combo aims to keep stomach cancer at bay longer

NCT ID NCT04021108

Ongoing Disease control Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether adding radiation therapy to the immunotherapy drug nivolumab can help people with advanced gastroesophageal cancer live longer without their disease getting worse. All 80 participants first receive a short course of chemotherapy (FOLFOX) plus nivolumab. Those whose cancer does not grow are then randomly assigned to continue nivolumab alone or nivolumab plus radiation. The main goal is to see how many patients are still progression-free after 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (Opdivo) and radiation therapy
What this could lead to: If successful, this could point toward a more effective treatment strategy for advanced gastroesophageal cancer, potentially extending the time patients live without their cancer growing.
What could go wrong: This is a small, early-phase study (80 people) and results may not apply to all patients. Adding radiation to immunotherapy also carries risks of increased side effects, and the benefit over standard care is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROESOPHAGEAL ADENOCARCINOMA

Contacts and locations

Locations

Moffitt Cancer Center

Tampa, Florida, 33612, United States
Roswell Park Cancer Center

Buffalo, New York, 14203, United States
University of Nebraska

Omaha, Nebraska, 68105, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Weill Cornell Medicine

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.